Related Experiment Video

Updated: Aug 18, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

Trop-2 as a Therapeutic Target in Breast Cancer

Elizabeth Sakach1, Ruth Sacks1, Kevin Kalinsky1

  • 1Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

Cancers
|December 11, 2022
PubMed

Insights

Trop-2 targeted therapies offer new hope for advanced breast cancer patients. Sacituzumab govitecan shows survival benefits, with more Trop-2 inhibitors in development for various breast cancer subtypes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Therapeutics

Background:

  • Trop-2 is a transmembrane protein increasingly recognized as a therapeutic target in breast cancer.
  • High Trop-2 expression is noted in triple-negative breast cancer (TNBC) but is present across all breast cancer subtypes.
  • Limited treatment options exist for patients with heavily pretreated advanced and metastatic breast cancer.

Purpose of the Study:

  • To review the emergence of Trop-2 as a therapeutic target in breast cancer.
  • To discuss the impact of Trop-2 inhibition on patient outcomes.
  • To explore ongoing and future directions for Trop-2 targeted therapies.

Main Methods:

  • Review of current literature on Trop-2 targeted therapies.
  • Analysis of clinical trial data for Trop-2 inhibitors, including sacituzumab govitecan.
  • Discussion of combination strategies and neoadjuvant/adjuvant applications.

Main Results:

  • Sacituzumab govitecan, a Trop-2 inhibitor, has demonstrated survival benefits in metastatic TNBC and hormone receptor-positive breast cancer.
  • Trop-2 inhibition is being investigated in combination regimens with immunotherapy and PARP inhibitors.
  • Studies are evaluating Trop-2 inhibition in early-stage breast cancer (neoadjuvant and adjuvant settings).

Conclusions:

  • Trop-2 targeted therapies represent a significant advancement for patients with advanced and metastatic breast cancer, particularly those with limited options.
  • Further research into novel Trop-2 targeted therapies and combination strategies holds promise for improving breast cancer treatment outcomes.
  • The therapeutic potential of Trop-2 inhibition is being explored across different stages and subtypes of breast cancer.
Keywords:
Trop-2antibody drug conjugatebreast cancer

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K